$0.87
1.93% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Stock price

$0.87
+0.12 15.45% 1M
-1.05 54.61% 6M
-0.87 49.91% YTD
-3.36 79.40% 1Y
-201.70 99.57% 3Y
-4,885.61 99.98% 5Y
-164,963.93 100.00% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.02 1.93%
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Key metrics

Market capitalization $4.53m
Enterprise Value $1.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 18.83
P/S ratio (TTM) P/S ratio 75.50
P/B ratio (TTM) P/B ratio 1.74
Revenue growth (TTM) Revenue growth -67.76%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-12.28m
Free Cash Flow (TTM) Free Cash Flow $-10.00m
Cash position $3.55m
EPS (TTM) EPS $-3.02
P/E forward negative
P/S forward 45.30
EV/Sales forward 11.30
Short interest 1.28%
Show more

Is Sonnet BioTherapeutics Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

Buy
100%

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.06 0.06
65% 65%
100%
- Direct Costs 0.08 0.08
14% 14%
133%
-0.03 -0.03
130% 130%
-50%
- Selling and Administrative Expenses 5.87 5.87
22% 22%
9,783%
- Research and Development Expense 6.30 6.30
57% 57%
10,500%
-12 -12
45% 45%
-20,333%
- Depreciation and Amortization 0.08 0.08
14% 14%
133%
EBIT (Operating Income) EBIT -12 -12
45% 45%
-20,460%
Net Profit -7.99 -7.99
65% 65%
-13,317%

In millions USD.

Don't miss a Thing! We will send you all news about Sonnet BioTherapeutics Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral
GlobeNewsWire
3 days ago
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.
Neutral
GlobeNewsWire
19 days ago
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy
Neutral
GlobeNewsWire
24 days ago
Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)
More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office United States
CEO Pankaj Mohan
Employees 12
Founded 2011
Website www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today